SGN-CD19A: Additional Phase I data

Interim data from 29 evaluable patients with relapsed or refractory B cell ALL, Burkitt lymphoma or B cell lymphoblastic lymphoma in an open-label, dose-escalation, U.S. Phase I trial showed that once...